Topic

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Articles

The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.

Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space

Cheryl Barton is director of PharmaVision, 

The European Union is discussing ways to reduce Europe’s over-reliance on imports of APIs.

EU to Support the Production of APIs and Finished Medicines within Europe  

Siegfried Schmitt, PhD, is Vice President Technical at Parexel International, Siegfried.Schmitt@parexel.com.

While global harmonization exists, there are still differences between the US and European GMP requirements that manufacturers should know, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.

Complying with European versus US GMPs 

Aviva Capital Partners and developer Socius are investing £1 billion to develop a cancer research and treatment center in Sutton, London.

Cancer Research and Treatment Center Planned for London

Mike Hennessy Jr. is the Chairman and CEO of 

The pharma industry is focused on strengthening its foundation, embracing innovation, and future-proofing its path forward.

Quality, Resilience, and Reinvention in Pharma Manufacturing

Bempikibart (ADX-914) is a human anti-IL-7Rα antibody that blocks the IL-7 and TSLP pathways, which have been implicated in driving T cell-mediated pathological processes in autoimmune diseases.

FDA Grants Fast Track Designation to Q32 Bio Treatment for Alopecia Areata

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Videos

Pharmaceutical Technology® spoke with Alexander Seyf, CEO and co-founder of Autolomous, about the impact geopolitical changes in Europe might have on the bio/pharmaceutical industry.

Industry Outlook 2025: European Geopolitical Impact on Pharma

Pharmaceutical Technology® spoke with Alexander Seyf, CEO and co-founder of Autolomous, about how the political landscape may impact the pharmaceutical industry.

Industry Outlook 2025: Political Implications for Pharma

The company said that Vyvgart (efgartigimod alfa) is the first novel mechanism of action for CIDP treatment in more than 30 years.

Quality Systems